Abstract
Peptides and proteins have been known for more than a century, but was only when du Vigneaud published the first synthesis of oxytocin, that the research on bioactive peptides was truly launched. Since then, the scientific progresses in the field have been astonishing and the synthesis of peptides of virtually any size and complexity is now possible. Perhaps the most important milestone was the development of the solid-phase peptide synthesis (SPPS) by Merrifield (1963), to revolutionize the field. In this critic review, we will analyze how the SPPS contributed to widespread the manufacture of peptides as active pharmaceuticals and what will be the challenges of tomorrow in this field.
Keywords: SPPS, LPPS, fmoc-chemistry, molecular machine, native chemical ligation.
Current Bioactive Compounds
Title:The Evolution of Peptide Synthesis: From Early Days to Small Molecular Machines
Volume: 9 Issue: 3
Author(s): Adriano Mollica, Francesco Pinnen, Stefanucci Azzurra and Roberto Costante
Affiliation:
Keywords: SPPS, LPPS, fmoc-chemistry, molecular machine, native chemical ligation.
Abstract: Peptides and proteins have been known for more than a century, but was only when du Vigneaud published the first synthesis of oxytocin, that the research on bioactive peptides was truly launched. Since then, the scientific progresses in the field have been astonishing and the synthesis of peptides of virtually any size and complexity is now possible. Perhaps the most important milestone was the development of the solid-phase peptide synthesis (SPPS) by Merrifield (1963), to revolutionize the field. In this critic review, we will analyze how the SPPS contributed to widespread the manufacture of peptides as active pharmaceuticals and what will be the challenges of tomorrow in this field.
Export Options
About this article
Cite this article as:
Mollica Adriano, Pinnen Francesco, Azzurra Stefanucci and Costante Roberto, The Evolution of Peptide Synthesis: From Early Days to Small Molecular Machines, Current Bioactive Compounds 2013; 9 (3) . https://dx.doi.org/10.2174/157340720903140119151919
DOI https://dx.doi.org/10.2174/157340720903140119151919 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews Screening and Identification of Inhibitors Against Glutathione Synthetase, A Potential Drug Target of Plasmodium falciparum
Combinatorial Chemistry & High Throughput Screening Early Decision: Effector and Effector Memory T Cell Differentiation in Chronic Infection
Current Immunology Reviews (Discontinued) Pharmacological Management of Hypertension in the Elderly - Certitudes and Controversies
Current Pharmaceutical Design Non-glycemic Adverse Effects of Insulin
Current Diabetes Reviews Glucose Tolerance Status in Pregnancy: A Window to the Future Risk of Diabetes and Cardiovascular Disease in Young Women
Current Diabetes Reviews In vitro and In silico Analysis of β-lactam Derivatives as Antimycobacterial Agents
Letters in Drug Design & Discovery Prolactin Induces IL-2 Associated TRAIL Expression on Natural Killer Cells from Chronic Hepatitis C Patients <i>In vivo</i> and <i>In vitro</i>
Endocrine, Metabolic & Immune Disorders - Drug Targets The Relationship between Diet and Frailty in Aging
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Atypical Antipsychotic Agents in the Treatment of Schizophrenia and Schizoaffective Disorders in the Elderly
Current Drug Safety The use of Immunoglobulin Therapy in Primary Immunodeficiency Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine
Current Cancer Drug Targets Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?
Current Cardiology Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design Novel Strategies to Ameliorate Radiation Injury: A Possible Role for Tetrahydrobiopterin
Current Drug Targets Meet Our Associate Editor
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) RNA Silencing: Recent Developments on miRNAs
Recent Patents on DNA & Gene Sequences Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs
Recent Patents on CNS Drug Discovery (Discontinued) Antiprotozoal Agents: An Overview
Anti-Infective Agents in Medicinal Chemistry